FDA
-
-
-
-
-
-
-
FDA approves NovoCure's Optune Pax for locally advanced pancreatic cancer
-
-
-
-
-
-
-
NovoCure submits FDA application for pancreatic cancer treatment
-
-
-
-
-
-
-
Novocure Reports First Quarter 2025 Financial Results
-
-
-
-
-
-
-
FDA Approves Novocure’s Innovative HFE Transducer Arrays for Use With Optune Gio® for Glioblastoma
-
-
-
-
-
-
-
NovoCure Ltd. (NVCR) PT Lowered to $22 at H.C. Wainwright
-
-
-
-
-
-
-
Novocure Announces Preliminary Full Year and Fourth Quarter 2023 Net Revenues and Provides Company Update
-
-
-
-
-
-
-
ROSEN, NATIONAL TRIAL COUNSEL, Encourages NovoCure Limited Investors to Secure Counsel Before Important Deadline in Securities Class Action – NVCR
-
326,540 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

